Serum Sulfhydryl Groups, Malondialdehyde, Uric Acid, and Bilirubin as Predictors of Adverse Outcome in Heart Failure Patients due to Ischemic or Nonischemic Cardiomyopathy

Table 2

Redox parameters of the examined group and comparison of subgroups separated on the basis of prognosis (median (25^th-75^th percentiles)).

	ICM			nICM		C vs. D,	A vs. C,	B vs. D,	ANOVA (A-D)
	A (), death or HT	B (), without endpoint	A vs. B,	C (), death or HT	D (), without endpoint
TAC (mmol/L)	1.13 (1.02-1.27)	1.14 (1.040-1.25)	0.861	1.140 (1.060-1.250)	1.08 (0.98-1.21)	0.017	0.759	<0.001	<0.001
TOS (mmol/L)	5.15 (4.10-6.60)	4.70 (4.000-5.90)	0.227	5.40 (4.45-6.60)	5.10 (4.20-6.05)	0.105	0.298	0.126	0.069
Uric acid (μmol/L)	44.55 (36.20-59.90)	39.90 (32.30-49.30)	0.002	42.35 (35.90-56.95)	40.80 (31.40-48.45)	0.068	0.699	0.642	0.002
Bilirubin (μmoL/L)	14.80 (10.10-24.70)	12.30 (9.10-18.60)	0.036	20.55 (13.80-33.00)	14.70 (10.00-20.60)	<0.001	0.007	0.014	<0.001
PSH (μmol/g of protein)	3.85 (3.10-5.00)	4.10 (3.100-5.300)	0.592	4.45 (3.100-5.450)	4.80 (3.80-5.60)	0.146	0.317	<0.001	<0.001
MDA (μmol/L)	2.00 (1.60-2.40)	1.80 (1.400-2.100)	<0.001	1.90 (1.500-2.250)	1.70 (1.30-2.00)	0.024	0.162	0.144	<0.001
MDA/PSH ratio	0.52 (0.36-0.74)	0.41 (0.308-0.622)	0.004	0.42 (0.291-0.705)	0.35 (0.26-0.50)	0.029	0.146	<0.001	<0.001

TAC: total antioxidant capacity; TOS: total oxidant status; MDA: malondialdehyde; PSH: sulfhydryl groups; A: ICM patients (EP+); B: ICM patients (EP-); C: nICM patients (EP+); D: nICM patients (EP-).